Status:
COMPLETED
Observational Retrospective Study To Characterize and Assess Clinical Outcomes of Patients Receiving Tezepelumab in the Framework Of Use in Special Situations Prior to Commercialisation in Spain
Lead Sponsor:
AstraZeneca
Conditions:
Severe Asthma
Eligibility:
All Genders
12+ years
Brief Summary
The aim of this study is to provide the first results on the use of tezepelumab under clinical practice conditions in severe asthma patients who participated in the "foreign medication supply" program...
Eligibility Criteria
Inclusion
- Subjects 12 years and older with severe asthma who were inadequately controlled with high dose inhaled corticosteroids plus another medicinal product
- Received at least one dose of tezepelumab under the FMS program, established according to Royal Decree 1015 / 2009 (prior to commercialization)
Exclusion
- Subjects having received tezepelumab or any other biologic for the treatment of asthma in the context of a clinical trial at any time during the 12 months prior to the index date.
Key Trial Info
Start Date :
June 17 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 25 2024
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT06487065
Start Date
June 17 2024
End Date
October 25 2024
Last Update
October 2 2025
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Alcázar de San Juan, Spain
2
Research Site
Almería, Spain
3
Research Site
Badajoz, Spain
4
Research Site
Bilbao, Spain